We review the challenges that have affected biosimilar utilization to date and investigate key dynamics within oncology markets likely to impact uptake of biosimilars going forward using quantitative simulation models. READ MORE
Budget Impact of Patient-Administered Biologic, Biosimilar for Patients With Non-Myeloid Malignancies
A budget impact analysis estimates the effective annual plan per-patient drug costs of a supportive care biologic and biosimilar to decrease significantly with respect to the original therapy.
Comparative Effectiveness Study Examines Safety, Efficacy of Biosimilar in Clinical Trial, Real-World Practice
The results from a randomized controlled trial were compared with a real-world cohort for the safety and efficacy of a biosimilar to treat chemotherapy-induced neutropenia in patients with breast cancer.
A comparative effectiveness study examined clinical outcomes and costs after treatment with a febrile neutropenia therapy vs a biosimilar for patients with non-myeloid cancer undergoing chemotherapy.
Robert M Rifkin, MD, FACP, gave an update on the basics, education, and reimbursement of biosimilars, stating that “this will be a huge year” for the the copycat biologics in the United States.
Implications of Manufacturer Contracting: A Quantitative Model to Assess Biosimilar Market Feasibility
We review the challenges that have affected biosimilar utilization to date and investigate key dynamics within oncology markets likely to impact uptake of biosimilars going forward using quantitative simulation models.
Researchers identified critical educational gaps that need to be addressed by manufacturers and policymakers in order for biosimilars to achieve their potential for lowering the cost of cancer care in the United States.
The European Medicines Agency approved its first biosimilar product in 2006; the United States biosimilar market remains in its infancy. The United States must look to the European Union as biosimilar adoption continues to grow.
Winston Wong, PharmD, breaks down the ASCO position statement on the utilization of biosimilars in oncology and ways in which the anticipated cost-savings may be achieved.
Gary Lyman, MD, MPH, explains the process of bringing oncology biosimilars to market and their potential uptake in clinical practice as well as pathways.
A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.